D-0029-2026 Class II Ongoing
FDA drug recall D-0029-2026 was initiated by Rising Pharma Holding, Inc. on Oct 7, 2025 and is designated Class II. Reason for recall: Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength… The recall status is ongoing. Affected quantity: 2,064 100-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 22, 2025
- Initiation Date
- Oct 7, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,064 100-count bottles
Product description
Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ, 08816, Manufactured by Suven Pharmaceuticals Limited, Pashamylaram, Telangana, 205307, India. NDC# 16571-691-01
Reason for recall
Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).
Distribution pattern
Distributed Nationwide in the USA
Code information
Lot # CS25070, exp. date 03/31/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0029-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026